8-K: Klotho Neurosciences Amends Forward Share Agreement

Klotho Neurosciences, Inc. has amended its forward purchase agreement with Meteora entities, extending the valuation date and fixing the maximum number of shares.

Summary

• Klotho Neurosciences, Inc. (the Company) entered into a Second Amendment to its Forward Purchase Agreement Confirmation with Meteora Capital Partners, LP, Meteora Select Trading Opportunities Master, LP, Meteora Strategic Capital, LLC, and Meteora Special Opportunity Fund I, LP (collectively, Seller) on September 19, 2025.
• The Valuation Date for the agreement was extended to the earlier of September 18, 2026, or specific trigger events.
• The maximum number of shares applicable to the agreement was fixed at 6,755,000 shares, which will not be decreased or increased (except for stock splits or dividends).
• The Reset Price was set to initially be $10.00, subject to weekly reset commencing 30 days after the business combination closing, to be the lesser of the Initial Price and the VWAP Price of the Shares of the prior trading week.
• The section titled 'Dilutive Offering Reset' was deleted in its entirety from the agreement.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The extension of the agreement's valuation date and the fixing of the maximum number of shares provide increased certainty and a longer runway for the company's financing. While the VWAP-based reset price introduces some volatility, the overall clarity and extended term are beneficial.

Positives

• The extension of the Valuation Date to September 18, 2026, provides Klotho Neurosciences with a longer runway for this financing arrangement.
• Fixing the Maximum Number of Shares at 6,755,000 reduces uncertainty regarding potential future dilution from this specific agreement.
• The deletion of the 'Dilutive Offering Reset' clause may simplify the agreement and remove a potential trigger for downward adjustments to the forward price based on future dilutive offerings.

Negatives

• The Reset Price mechanism, which ties the price to the lesser of the Initial Price and the prior week's VWAP, introduces potential volatility and could result in a lower effective price if the stock's VWAP declines.

Risks

• The Valuation Date can be accelerated by the Seller upon the occurrence of specific events, including a Shortfall Variance Registration Failure, a VWAP Trigger Event, a Delisting Event, a Registration Failure, or any Additional Termination Event.
• Fluctuations in the Company's stock price (VWAP) could impact the Reset Price, potentially affecting the value of the shares under the agreement.

Future Outlook

The amendment extends the operational term of the forward purchase agreement, providing Klotho Neurosciences with a longer period for this financing arrangement to mature, with the Valuation Date now set for September 18, 2026, subject to earlier termination triggers.

Management Comments

• Joseph Sinkule, Chief Executive Officer, signed the 8-K filing on behalf of Klotho Neurosciences, Inc.
• Jeffrey LeBlanc, Chief Financial Officer, signed the Second Amendment to the Forward Purchase Agreement Confirmation on behalf of Klotho Neurosciences Inc.

Industry Context

This amendment reflects ongoing adjustments to financing agreements, which are common for emerging growth companies, particularly those that have recently completed a business combination (e.g., SPAC mergers). Forward purchase agreements are a standard mechanism for securing capital and managing share structures in such contexts.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders benefit from the increased clarity regarding the maximum potential dilution from this specific forward purchase agreement, as the maximum number of shares has been fixed.
• The extension of the agreement's term provides more time for the company to execute its strategic plans before the final valuation of the forward purchase.

Next Steps

• The Forward Purchase Agreement Confirmation, as amended, will continue in full force and effect until the new Valuation Date of September 18, 2026, or an earlier trigger event.

Key Dates

Recommendation

The amendment provides greater clarity and extends the duration of a significant financing agreement, which reduces uncertainty for investors. However, it does not fundamentally alter the company's operational performance or strategic direction in a way that would warrant a strong buy or sell recommendation based solely on this filing. The fixed maximum shares are a positive, while the VWAP-linked reset price introduces some market-dependent risk. Therefore, a 'hold' recommendation is appropriate as investors assess the company's broader performance and market conditions.

Keywords

Klotho Neurosciences, KLTO, SEC filing, 8-K, Forward Purchase Agreement, Subscription Agreement, Meteora Capital, Share agreement, Valuation Date, Maximum Shares, Reset Price, Financing, Neurosciences